Current influenza treatment options include oral or inhaled antiviral agents. There is an unmet need for parenteral antiviral treatments.
Methods
Peramivir, a parenteral influenza neuraminidase inhibitor (NAI), was administered by single-dose intramuscular (IM) injection in two placebo-controlled studies in adult outpatients with acute, uncomplicated influenza during two consecutive influenza seasons.
Results
In a Phase II study, peramivir treatment significantly shortened duration of fever and reduced viral load in nasopharyngeal secretions. A subsequent Phase III study was not fully enrolled; however, in both studies, the magnitude of the treatment effect favouring peramivir was consistent with that reported for other NAIs. A post-hoc analysis was conducted by integrating efficacy and safety results of 427 subjects from both studies. The median time to alleviation of symptoms (TTAS) in subjects receiving peramivir 300 mg (113.2 h) was shorter than for placebo (134.8 h; P=0.161 adjusted for smoking behaviour, influenza season and virus type; unadjusted P=0.047). The median time to resolution of fever was reduced by 24 h after treatment with peramivir 300 mg compared with placebo (P=0.004). The proportion of subjects shedding influenza virus was significantly decreased over 48 h following peramivir treatment (P=0.009). Detection of post-treatment viruses with decreased susceptibility to NAIs was uncommon. Peramivir was generally safe and well-tolerated with types and rates of adverse event similar to placebo.
Conclusions
The results of these studies are consistent with previous reports of peramivir administered by intravenous infusion, and demonstrate a positive risk–benefit profile for peramivir in patients with acute uncomplicated influenza.
References
1.
HarperS.A., BradleyJ.S., EnglundJ.A.Seasonal influenza in adults and children – diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.Clin Infect Dis2009; 48: 1003–1032.
BantiaS., ParkerC.D., AnanthS.L.Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.Antimicrob Agents Chemother2001; 45: 1162–1167.
4.
GubarevaL.V., TrujilloA.A., Okomo-AdhiamboM.Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.Antivir Ther2010; 15: 1151–1159.
5.
CaoR.Y., XiaoJ-H, CaoB., LiS., KumakiY., ZhongW.Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.Antivir Chem Chemother2013; 23: 237–240.
6.
BabuY.S., ChandP., BantiaS.BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.J Med Chem2000; 43: 3482–3486.
7.
BantiaS., ArnoldC.S., ParkerC.D., UpshawR., ChandP.Anti-influenza virus activity of peramivir in mice with single intramuscular injection.Antiviral Res2006; 69: 39–45.
8.
Kohno S, Kida H, Masashi M, Shimada J, S-021812 Clinical Study Group.Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.Antimicrob Agents Chemother2010; 54: 4568–4574.
9.
WetherallN.T., TrivediT., ZellerJ.Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the Neuraminidase Inhibitor Susceptibility Network.J Clin Microbiol2003; 41: 742–750.
10.
TreanorJ.J., HaydenF.G., VroomanP.S.Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial.JAMA2000; 283: 1016–1024.
11.
NicholsonK.G., AokiF.Y., OsterhausA.D.M.E.Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial.Lancet2000; 355: 1845–1850.
12.
MontoA.S., FlemingD.M., de GrootR.Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections.J Infect Dis1999; 180: 254–261.
13.
HsuJ., SantessoN., MustafaR.Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies.Ann Intern Med2012; 156: 512–524.
CooperN.J., SuttonA.J., AbramsK.R., WailooA., TurnerD., NicholsonK.G.Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomized controlled trials.BMJ2003; 326: 1235.
